Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

SCTX

Scribe Therapeutics Inc

18.97

Jul 27 • 3:59 PM ET -2.68 (-12.38%)

18.97

Aftermarket • 7:34 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Jul 27, 4:40 PMScribe Therapeutics closes upsized Nasdaq IPO and Sanofi private placement, raising approximately $155.5 million in gross proceeds

Held by: ARKG HLTH

Scroll to Statements

Index	-
Market Cap	306.97M
Enterprise Value	423.93M
Income	-
Sales	-
Book/sh	-9.03
Cash/sh	3.07
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	98
IPO	Jul 24, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	6.17
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.66
Current Ratio	0.66
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	-
Insider Trans	-
Inst Own	6.47%
Inst Trans	-
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-6.60%
SMA50	-6.60%
SMA200	-6.60%
Trades

Shs Outstand	16.18M
Shs Float	-
Short Float	-
Short Ratio	-
Short Interest	-
52W High	25.49 -25.58%
52W Low	21.00 -9.67%
Volatility	- -
ATR (14)	4.97
RSI (14)	-
Beta	-
Rel Volume	0.42
Avg Volume	990.79K
Volume	419,109

Perf Week	-
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	-24.12%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	21.65
Price	18.97
Change	-12.38%

Jul-27-26 04:08PM	Scribe's Genetic Editing Aims to Prevent Heart Attacks (Barrons.com) -12.38%
04:05PM	Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement (GlobeNewswire)
Jul-24-26 02:45PM	Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO (GuruFocus.com)

Scribe Therapeutics, Inc. is a clinical-stage biotechnology company. It is engaged in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded in June 2017 by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Alameda, CA.

Co-Founder & Scientific AdvisorDr. Jennifer A. Doudna Ph.D.

Co-Founder & VP of External InnovationMr. Brett T. Staahl Ph.D.

Co-Founder & Scientific AdvisorMr. David F. Savage Ph.D.

VP & ControllerMr. George Manning F.C.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lucas Svetlana	Chief Business Officer	Jul 23 '26	Buy	15.00	3,000	45,000	3,000	Jul 27 09:42 PM
Parrot David	Chief Financial Officer	Jul 23 '26	Buy	15.00	2,666	39,990	1,333	Jul 27 09:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SCTX

Scribe Therapeutics Inc

Upgrade your Finviz experience